April 18, 2024 EU Moves Toward Single Capital Market Union
April 17, 2024 Bitcoin Halving 2024: Market Impact Predictions
April 14, 2024 Markets Rattle: Iran-Israel Conflict and Economic Data Ahead
April 12, 2024 Banks Brace for Earnings Amid Rate Cut Speculations
Apple’s Technical Climb To $240 By Year-End
April 12, 2024 Improve Your Financial Status: A How-To Guide
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
Protagonist Therapeutics (PTGX) Stock Forecast for 2024–2028. Sell or Buy?
Updated: April 18, 2024 (05:11)
Sector: HealthcareThe share price of Protagonist Therapeutics, Inc. (PTGX) now
50/200 Day Moving Average: $28.5 / $21.74
This figure corresponds to the Average Price over the previous 50/200 days. For Protagonist Therapeutics stocks, the 50-day moving average is the support level today.
For Protagonist Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in Protagonist Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Protagonist Therapeutics stock price in 2024, 2025, 2026, 2027, 2028. How much will one Protagonist Therapeutics share be worth in 2024 - 2028?
When should I take profit in Protagonist Therapeutics stock? When should I record a loss on Protagonist Therapeutics stock? What are analysts' forecasts for Protagonist Therapeutics stock? What is the future of Protagonist Therapeutics stock? We forecast Protagonist Therapeutics stock performance using neural networks based on historical data on Protagonist Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Protagonist Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Protagonist Therapeutics shares. This happens once a day.
Historical and forecast chart of Protagonist Therapeutics stock
The chart below shows the historical price of Protagonist Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Protagonist Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
“Protagonist Therapeutics, Inc.” is a clinical stage biopharmaceutical company with a peptide technology platform focused on the discovery and development of new chemical entities (NECs) to meet significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. His main focus is on the development of oral peptide formulations that target biological pathways, also targeting commercially available injectable antibodies. PTG-100 is an oral peptide product of an alpha-4-beta-7 (a4b7) integrin antagonist candidate who has completed a phase I clinical trial in normal healthy volunteers (NHVs). PTH-100 is being developed for the treatment of moderate to severe ulcerative colitis (UC). PTG-200 is an oral interleukin-23 (IL-23R) receptor antagonist being developed for the treatment of moderate to severe Crohn’s disease. PTG-300 is an injectable hepcidin mimetic for the treatment of rare conditions associated with iron overload.
Protagonist Therapeutics daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Apr 20 | 28.65 | 28.18 | 28.97 | 2.80 |
| Apr 21 | 28.90 | 28.27 | 29.25 | 3.43 |
| Apr 22 | 28.15 | 27.78 | 28.63 | 3.08 |
| Apr 23 | 27.76 | 27.46 | 28.15 | 2.49 |
| Apr 24 | 27.49 | 27.05 | 27.79 | 2.73 |
| Apr 25 | 27.81 | 27.11 | 28.49 | 5.09 |
| Apr 26 | 27.87 | 27.22 | 28.24 | 3.74 |
| Apr 27 | 28.13 | 27.48 | 28.70 | 4.42 |
| Apr 28 | 28.54 | 28.17 | 28.95 | 2.79 |
| Apr 29 | 27.89 | 27.55 | 28.25 | 2.56 |
| Apr 30 | 28.14 | 27.47 | 28.56 | 3.97 |
| May 01 | 27.83 | 27.50 | 28.35 | 3.11 |
| May 02 | 28.11 | 27.82 | 28.50 | 2.46 |
| May 03 | 27.93 | 27.23 | 28.55 | 4.86 |
| May 04 | 27.57 | 26.90 | 28.10 | 4.46 |
| May 05 | 27.73 | 27.50 | 28.14 | 2.32 |
| May 06 | 27.61 | 27.00 | 28.05 | 3.89 |
| May 07 | 28.45 | 28.08 | 29.06 | 3.50 |
| May 08 | 28.03 | 27.40 | 28.44 | 3.76 |
| May 09 | 27.57 | 27.39 | 28.07 | 2.48 |
| May 10 | 27.95 | 27.66 | 28.37 | 2.56 |
| May 11 | 27.96 | 27.50 | 28.63 | 4.10 |
| May 12 | 28.44 | 28.20 | 28.86 | 2.32 |
| May 13 | 29.08 | 28.51 | 29.28 | 2.71 |
| May 14 | 29.27 | 28.79 | 29.53 | 2.57 |
| May 15 | 28.92 | 28.72 | 29.59 | 3.03 |
| May 16 | 28.81 | 28.48 | 29.42 | 3.30 |
| May 17 | 28.81 | 28.20 | 29.05 | 3.01 |
| May 18 | 28.49 | 28.12 | 28.81 | 2.46 |
| May 19 | 27.74 | 27.45 | 28.20 | 2.75 |
Protagonist Therapeutics Daily Price Targets
Protagonist Therapeutics Stock Forecast 04-20-2024.
Forecast target price for 04-20-2024: $28.65.
Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.722%.
Pessimistic target level: 28.18
Optimistic target level: 28.97
Protagonist Therapeutics Stock Forecast 04-21-2024.
Forecast target price for 04-21-2024: $28.90.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 3.320%.
Pessimistic target level: 28.27
Optimistic target level: 29.25
Protagonist Therapeutics Stock Forecast 04-22-2024.
Forecast target price for 04-22-2024: $28.15.
Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.989%.
Pessimistic target level: 27.78
Optimistic target level: 28.63
Protagonist Therapeutics Stock Forecast 04-23-2024.
Forecast target price for 04-23-2024: $27.76.
Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.430%.
Pessimistic target level: 27.46
Optimistic target level: 28.15
Protagonist Therapeutics Stock Forecast 04-24-2024.
Forecast target price for 04-24-2024: $27.49.
Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.659%.
Pessimistic target level: 27.05
Optimistic target level: 27.79
Protagonist Therapeutics Stock Forecast 04-25-2024.
Forecast target price for 04-25-2024: $27.81.
Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 4.841%.
Pessimistic target level: 27.11
Optimistic target level: 28.49
PTGX (PTGX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May. | 27.95 | 25.74 | 29.56 | 12.93 |
| Jun. | 30.54 | 29.29 | 32.92 | 11.02 |
| Jul. | 29.88 | 28.55 | 30.81 | 7.33 |
| Aug. | 26.83 | 25.03 | 27.70 | 9.65 |
| Sep. | 23.71 | 21.91 | 25.58 | 14.34 |
| Oct. | 25.56 | 23.72 | 26.69 | 11.14 |
| Nov. | 28.16 | 26.98 | 30.83 | 12.50 |
| Dec. | 29.82 | 28.17 | 32.61 | 13.61 |
Protagonist Therapeutics forecast for this year
Protagonist Therapeutics Stock Prediction for May 2024
An downtrend is forecast for this month with an optimal target price of $27.9544. Pessimistic: $25.74. Optimistic: $29.56
Protagonist Therapeutics Stock Prediction for Jun 2024
An uptrend is forecast for this month with an optimal target price of $30.5374. Pessimistic: $29.29. Optimistic: $32.92
Protagonist Therapeutics Stock Prediction for Jul 2024
An downtrend is forecast for this month with an optimal target price of $29.8778. Pessimistic: $28.55. Optimistic: $30.81
Protagonist Therapeutics Stock Prediction for Aug 2024
An downtrend is forecast for this month with an optimal target price of $26.8302. Pessimistic: $25.03. Optimistic: $27.70
Protagonist Therapeutics Stock Prediction for Sep 2024
An downtrend is forecast for this month with an optimal target price of $23.7072. Pessimistic: $21.91. Optimistic: $25.58
Protagonist Therapeutics Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $25.5563. Pessimistic: $23.72. Optimistic: $26.69
Protagonist Therapeutics Stock Prediction for Nov 2024
An uptrend is forecast for this month with an optimal target price of $28.1631. Pessimistic: $26.98. Optimistic: $30.83
Protagonist Therapeutics Stock Prediction for Dec 2024
An uptrend is forecast for this month with an optimal target price of $29.8191. Pessimistic: $28.17. Optimistic: $32.61
Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 31.47 | 29.28 | 33.99 | 13.88 |
| Feb | 35.05 | 32.74 | 36.27 | 9.74 |
| Mar | 36.27 | 33.53 | 37.19 | 9.83 |
| Apr | 35.01 | 32.74 | 38.03 | 13.92 |
| May | 38.92 | 37.56 | 42.56 | 11.74 |
| Jun | 42.00 | 39.23 | 43.56 | 9.95 |
| Jul | 43.36 | 40.13 | 44.82 | 10.45 |
| Aug | 46.07 | 43.74 | 47.34 | 7.59 |
| Sep | 45.40 | 43.99 | 48.62 | 9.53 |
| Oct | 47.04 | 44.27 | 50.31 | 12.00 |
| Nov | 45.96 | 44.53 | 47.12 | 5.50 |
| Dec | 45.74 | 42.07 | 47.83 | 12.05 |
Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 42.12 | 40.86 | 44.55 | 8.28 |
| Feb | 43.84 | 41.63 | 45.89 | 9.29 |
| Mar | 38.84 | 35.91 | 41.73 | 13.96 |
| Apr | 40.52 | 37.94 | 42.46 | 10.65 |
| May | 40.23 | 36.37 | 43.51 | 16.42 |
| Jun | 44.52 | 42.60 | 47.36 | 10.04 |
| Jul | 44.42 | 40.85 | 47.93 | 14.79 |
| Aug | 39.57 | 38.33 | 43.37 | 11.61 |
| Sep | 37.43 | 35.14 | 39.41 | 10.83 |
| Oct | 33.12 | 32.12 | 35.46 | 9.41 |
| Nov | 34.99 | 31.75 | 37.25 | 14.76 |
| Dec | 37.88 | 35.88 | 40.29 | 10.94 |
Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 40.70 | 38.11 | 42.61 | 10.55 |
| Feb | 44.85 | 41.35 | 48.51 | 14.76 |
| Mar | 42.92 | 41.27 | 45.49 | 9.28 |
| Apr | 41.01 | 38.89 | 42.19 | 7.81 |
| May | 44.60 | 41.77 | 47.92 | 12.84 |
| Jun | 49.04 | 46.93 | 50.57 | 7.21 |
| Jul | 46.98 | 44.05 | 51.38 | 14.26 |
| Aug | 49.58 | 46.90 | 52.85 | 11.26 |
| Sep | 48.03 | 46.42 | 50.91 | 8.83 |
| Oct | 46.36 | 43.02 | 49.81 | 13.63 |
| Nov | 48.42 | 46.27 | 50.63 | 8.61 |
| Dec | 49.81 | 45.93 | 53.64 | 14.38 |
Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2028
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 55.01 | 50.19 | 57.32 | 12.44 |
| Feb | 55.28 | 51.36 | 58.73 | 12.54 |
| Mar | 54.02 | 50.58 | 58.75 | 13.90 |
| Apr | 53.50 | 51.51 | 58.12 | 11.38 |
| May | 52.28 | 50.71 | 54.91 | 7.65 |
| Jun | 54.91 | 51.55 | 58.34 | 11.63 |
| Jul | 56.30 | 52.65 | 59.68 | 11.77 |
| Aug | 49.61 | 48.36 | 52.05 | 7.09 |
| Sep | 51.40 | 47.45 | 53.43 | 11.20 |
| Oct | 52.94 | 50.21 | 56.11 | 10.53 |
| Nov | 52.37 | 50.54 | 54.82 | 7.80 |
| Dec | 51.86 | 49.44 | 53.29 | 7.24 |
Protagonist Therapeutics information and performance
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, US
Market capitalization of the Protagonist Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PTGX shares in the company outstanding by the market price of one share.
EBITDA of Protagonist Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
